Skip to main content

Grace Therapeutics, Inc.

GRCE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001444192

In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.

Q1 2024 vs. Q4 2023

How the institutions holding Grace Therapeutics, Inc. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024All holders in Q4 2023

13F holders of GRCE: Q4 2023 compared with Q1 2024
MeasureQ4 2023Q1 2024Change
Holders910+1
Shares571.3K1.27M+694.2K (+121.5%)
Value$1.65M$4.34M+$2.68M (+162.6%)

New holders (3)

Institutions that held Grace Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to GRCE in Q1 2024
InstitutionSharesValue% of portfolio
AIGH Capital Management LLC497,359$1.71M0.82%
Susquehanna International Group, LLP36,650$126.4K0.00%
NBC Securities, Inc.2––

Sold out (2)

Institutions that held Grace Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.

Institutions that sold out of GRCE in Q1 2024
InstitutionShares, Q4 2023Value, Q4 2023
Advisory Services Network, LLC41$118
ICA Group Wealth Management, LLC9$26